Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski has initiated coverage on Collegium Pharmaceutical (NASDAQ: COLL) with an Outperform rating. The firm has set a price target of $50 for the stock.